- Pfizer Canada announced that BRAFTOVI (encorafenib) will be funded through Ontario’s Funding Accelerated for Specific Treatments (FAST) program for patients with metastatic colorectal cancer harboring a BRAF V600E mutation detected by a validated test.
- Ontario becomes the first province in Canada to reimburse BRAFTOVI for this indication following a positive recommendation from Canada’s Drug Agency, marking a major step toward faster access to precision oncology therapies.
- The FAST program aims to shorten the timeline between regulatory approval and public reimbursement, addressing long oncology drug wait times that average nearly 19 months across Canada.
- Pfizer, alongside advocacy groups including Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network, highlighted the funding decision as an important advancement for metastatic colorectal cancer patients facing limited treatment options and urgent care needs.
Takeaways:
Ontario’s reimbursement of BRAFTOVI is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined metastatic colorectal cancer segment where treatment options are limited, while also validating the FAST pathway as a faster route to public access for high-need therapies.
Market-wise, this improves near-term commercial potential in Ontario and could set a precedent for other provinces to follow, especially after a positive recommendation from Canada’s Drug Agency.
Source: CA Newswire
